The Europe Antibiotics Market is witnessing steady growth, driven by the increasing prevalence of infectious diseases, an aging population, and advancements in diagnostic capabilities. These factors ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

Regeneron posts their portion of Dupixent as collaboration revenue. Regeneron and Sanofi are seeking to expand the use of ...

The global acute respiratory distress syndrome (ARDS) treatment market was valued at approximately USD $$ billion in 2022 and is expected to grow at a robust CAGR of more than $% during the forecast ...

Brian Pacheco New York The writer is the managing director of communications for the Drug Policy Alliance. To the Editor: Nicholas Kristof’s column starts with a faulty and harmful premise ...

Across sensitivity and subgroup analyses, the results were consistent. “These findings suggest that SGLT-2is and GLP-1 RAs may be preferable to DPP4is when deciding among glucose-lowering medications ...

Study objectives: To identify the predictors of medication adherence in patients with COPD and contrast the health beliefs, experiences, and behaviors of COPD patients self-reporting good ...

Chronic pain is complex and difficult to treat. Prescribing opioid pain medications has become controversial but may help some patients. With the goal of informing clinician practice, a new study ...

COPD was the underlying disease condition in ... management based on how I am feeling" and "I get confused about my medications" were found to be significant independent predictors of nonadherence ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application (sBLA) seeking approval for Dupixent for treating bullous pemphigoid (BP), a ...